Oramed wins Chinese patent for oral core technology

Oramed ($ORMP), the Jerusalem-based developer of two oral diabetes products in clinical trials, landed approval for a Chinese patent of its core technology from the country's State Intellectual Property Office. The patent--Oramed's eighth--covers the company's methods and compositions for the oral administration of proteins. New Zealand and South Africa offices also granted patents, and Oramed has 27 more patents pending. Oramed has its orally ingestible insulin pill in Phase II and recently submitted a pre-IND for its oral exenatide capsule for Type 2 diabetes. Release